Pomegra
Danish biotech Samplix closed €25M in a first close led by WLanholding, but only €3M is new cash; the rest converts shareholder bonds ahead of a €30M target.
Key Takeaways
- Samplix announced a €25M first close on October 27, 2026, led by WLanholding GmbH.
- Only €3M is new capital; €22M comes from shareholder convertible bonds.
- The round targets €30M in total, and valuation was not disclosed.
Lead
Samplix, the Birkerød-based maker of the Xdrop single-cell screening platform, announced a €25M first close of its financing round on October 27, 2026. The round is led by WLanholding GmbH, a privately owned European investment firm founded by Werner Lanthaler, the former CEO of Evotec. All major existing shareholders took part. The company says the money will go toward commercial expansion of Xdrop in antibody discovery and biotherapeutic development.
What Did Samplix Raise, and Who Backed It?
Samplix raised €25M in a first closing, split into €3M of new capital and €22M from shareholder convertible bonds. WLanholding leads, and the round stays open to further investors with a total target of €30M. Valuation and the individual investment amounts were not disclosed.
Lanthaler is expected to join the Samplix board within the next year. His appointment ties the lead investor directly to governance, which is common when a lead takes a large stake in a company that needs hands-on commercial guidance.
Earlier backers include the EIC Accelerator, Vækstfonden, Horizon 2020 funding and Estibio, according to investor databases. Samplix was founded in 2013, so this round arrives after more than a decade of public and private funding.
What Does Xdrop Do?
Xdrop is a droplet microfluidics platform that screens single cells and recovers those producing antibodies with a desired function. It links an antibody's function to the cell that secretes it and to that cell's genetic sequence. The company says it runs on existing laboratory equipment, so labs do not need specialized instruments.
That positioning puts Xdrop against established single-cell and antibody screening systems from larger instrument vendors. Samplix's pitch is accessibility: a lab that cannot justify a dedicated high-throughput screening line can still run function-first selection. CEO Henrik Pfundheller said the investment validates "the value our Xdrop platform brings to the antibody discovery community."
Why Does the Conversion Matter More Than the Headline Number?
The €25M figure overstates the cash that reaches the company: €22M of it is existing debt converting, not money newly wired in. Filings for 2025 show a net loss of roughly US$8.1M and negative equity of about US$16.7M, along with an auditor going-concern warning. Converting bonds repairs that balance sheet, which is the stated purpose of the round alongside commercial expansion.
A balance-sheet restructuring led by an insider-adjacent investor reads differently from a growth round priced by outsiders. The absence of a disclosed valuation fits that reading. Existing shareholders chose to stay in rather than let the company seek rescue terms elsewhere, which signals some confidence, but it does not test what a new investor would pay.
The €3M of fresh capital is small against an annual loss of that size. On that run rate it covers a limited stretch of operations, which makes the remaining €5M of the target important.
What Comes Next for the Round?
Samplix needs to attract additional investors to reach the €30M target, and each further close would offer a cleaner read on how outsiders value the company. Lanthaler's pedigree at Evotec, a drug discovery services group, may help open doors to biopharma partners and customers. Those relationships matter because the company's plan rests on selling more Xdrop units and deepening ties with pharmaceutical and academic labs.
Two outcomes look plausible. If later closes bring in outside money at a disclosed price, the round will look like a recapitalization followed by growth funding. If the target stalls at the first close, Samplix enters 2027 with a repaired balance sheet but thin cash, and sales growth would have to carry the company.
Outlook
Samplix has cleaned up its balance sheet and gained a lead investor with sector credentials, but the new cash is €3M and the valuation remains private. The next closes toward €30M, and Xdrop sales through 2027, will show whether the platform's accessibility argument converts into revenue.
